Navigation Links
PAREXEL Consulting Releases Annual Analysis of FDA New Drug Review Trends
Date:10/26/2010

BOSTON, Oct. 26 /PRNewswire/ -- PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the "New Normal": Emerging FDA Review Outcome Trends for New Drugs.  Exploring trends in the review of new molecular entities (NMEs), as well as first-cycle approval and priority designation rates, PAREXEL Consulting's analysis indicates that there is a "new normal" emerging in the drug review and approval process.

PAREXEL Consulting's analysis identified notable declines in both first-cycle approval rates for priority drug applications and priority designation rates for new drugs at the time when the U.S. Food and Drug Administration (FDA) settled into its FDA Amendments Act (FDAAA)-related responsibilities and the 21st Century Review Process.  Between 2008 and 2009, for example, PAREXEL Consulting found that there was a 25 percent decline in first-cycle approval rates for priority-rated new drugs and a 17 percent decrease in priority designations for new drug applications (NDAs).

"First-cycle approval rates are a key indicator of the biopharmaceutical industry's success in securing FDA approval for new therapies early in the review process.  While there is often some fluctuation in first-cycle approval rates year-to-year, our analysis of the latest FDA metrics leads us to ask whether there is a 'new normal' emerging, which has significant implications for the drug-review process," said Mark Mathieu, Director of Strategic Research at PAREXEL Consulting.
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... Inc. (Nasdaq: SLTM ), a global leader in ... 69, Chief Technology Officer and a member of the company,s ... 1, 2010. Mr. DeBenedictis will be available to advise the ... to remain active in the development of other emerging medical ...
... Md., Sept. 15 The U.S. Food and Drug ... Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, ... company accepted responsibility for criminal actions including distribution of ... and obstruction of an FDA inspection. ...
Cached Medicine Technology:Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc. 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
(Date:5/22/2015)... Utah (PRWEB) May 22, 2015 Mountain Point ... host a ribbon cutting ceremony on Friday, May 29, 2015 ... p.m. to 6 p.m. The new medical center, set to ... North Triumph Boulevard, Lehi, UT 84043. , “The opening ... our team and the Utah County community,” said Kent Loosle, ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
(Date:5/22/2015)... Boston, Massachusetts (PRWEB) May 22, 2015 ... conditions is a difficult process. Historically providers have ... efforts by payers. Starting in 2015, Medicare has ... care coordination activities. Thanks to the launch of ... technology, providers and health systems using the platform ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
(Date:5/22/2015)... May 22, 2015 sweetFrog Enterprises, LLC. is ... Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store located ... was listed as #22 on the Inc. 500 list of ... lived and worked in East Texas for 20 years and ... owner of the Jacksonville, and nearby Palestine, sweetFrog locations. “We ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... Findings by UT Southwestern Medical Center researchers may suggest ... patients with blood cancers such as leukemia, lymphoma and myeloma. ... Cell , showed for the first time that adult blood ... that leads to transplant rejection. It also opens up further ...
... Kentucky on Aug. 3 announced that they were among the ... a lung transplant, using a device invented by two university ... "The device helps patients get oxygen into their blood ... dioxide and oxygenates the blood before returning it to the ...
... News) -- People with a rare condition where they are born ... study. The findings, published in the Aug. 4 online ... could shed light on how fingerprints are formed as well as ... the researchers pointed out. "We know that fingerprints are fully ...
... just one 4cl measure of spirits can increase the risk of ... appear to have the same effect, according to a study published ... Researchers from the Karolinska Institutet in Sweden followed 84,601 people ... in Vastmanland and Uppsala for a median of ten years. During ...
... (HealthDay News) -- The cost of dealing with health insurers ... than for Canadian physicians, a new study finds. The ... annually is $82,975 for U.S. physicians and $22,205 for physicians ... of the University of Toronto and colleagues. U.S. doctors ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 3 ... detect prostate cancer and better evaluate a patient,s treatment options, ... their physician can use to help them decide whether it,s ... said lead researcher Dr. Scott Tomlins, a pathology resident at ...
Cached Medicine News:Health News:New use of artificial lung device pioneered at University of Kentucky 2Health News:Gene Mutation Can Leave People Without Fingerprints 2Health News:Drinking just 1 measure of spirits increases the risk of acute pancreatitis 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 3
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... precious time and gain efficiency in ... Automation System (LAS), the high-throughput aliquotting ... capabilities. The Olympus OLA2500 LAS is ... for medium- to high-volume laboratories. As ...
Medicine Products: